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ABSTRACT
Background: Alternative endpoints to overall survival (OS) are frequently used 
to assess treatment efficacy in randomized controlled trials (RCT). Their properties in 
terms of surrogate outcomes for OS need to be assessed. We evaluated the surrogate 
properties of progression-free survival (PFS), time-to-progression (TTP) and  
time-to-treatment failure (TTF) in advanced soft tissue sarcomas (STS).
             Meta-Analysis
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Results: A total of 21 trials originally met the selection criteria and 14 RCTs  
(N = 2846) were included in the analysis. Individual-level associations were moderate 
(highest for 12-month PFS: Spearman’s rho = 0.66; 95% CI [0.63; 0.68]). Trial-level 
associations were ranked as low for the three endpoints as per the IQWiG criterion.
Materials and Methods: We performed a meta-analysis using individual-patient 
data (IPD). Phase II/III RCTs evaluating therapies for adults with advanced STS were 
eligible. We estimated the individual- and the trial-level associations between then 
candidate surrogates and OS. Statistical methods included weighted linear regression 
and the two-stage model introduced by Buyse and Burzykowski. The strength of the 
trial-level association was ranked according to the German Institute for Quality and 
Efficiency in Health Care (IQWiG) guidelines.
Conclusions: Our results do not support strong surrogate properties of PFS, TTP 
and TTF for OS in advanced STS.
INTRODUCTION
The choice of the primary endpoint is a key step 
when designing a randomized controlled trial (RCT). In 
oncology, the most commonly used endpoint to assess the 
efficacy of a new treatment in RCTs is overall survival 
(OS) which is easily measurable, objectively defined as 
the time from randomization to death and validated by 
health regulatory authorities [1]. Alternative time-to-
event endpoints are commonly used in practice in phase 
II trials and increasingly being used instead of OS in 
phase III trials [2]. These composite endpoints include 
biological and clinical events, such as disease progression 
or treatment toxicity. Their development is driven by the 
need to reduce the number of patients, the trial duration, 
the delay to reach conclusions and ultimately the cost of 
the trials. However, it is essential to rigorously assess their 
surrogate properties for OS, and as such whether or not 
they can be used as primary endpoints for assessing the 
benefit of new therapies. This approach does not preclude 
their intrinsic value as parameters of patient benefit of a 
treatment.
As of today, the meta-analytic surrogacy evaluation 
scheme proposed by Buyse and Burzykowski et al. [3, 4] 
is considered as the most statistically rigorous method for 
the validation of surrogate endpoints [5, 6]. This approach 
requires individual-patient data (IPD) from multiple RCTs 
with similar design and treatment to address surrogacy 
from a multi-level framework. At the patient level, the 
surrogate endpoint should be correlated and predictive of 
the final endpoint regardless of the treatment (individual-
level association). At the trial level, the treatment effect on 
the surrogate endpoint should be correlated and predictive 
of the treatment effect on the final endpoint (trial-level 
association). 
Soft-tissue sarcomas (STS) are a heterogeneous 
group of diseases that account for 1% of all malignancies 
in adults [7]. Despite adequate locoregional treatment, up 
to 40% of patients with STS develop metastatic disease 
[7]. When metastases are detected, the standard of care 
is palliative chemotherapy. Due to their rarity, conducting 
large RCTs to evaluate the benefit of new treatment for 
metastatic STS is complex. The identification of valid 
surrogate endpoints for OS that would reduce the number 
of included patients would be of a great advantage for 
clinical research. To our knowledge, only one meta-
analysis evaluating response rate and PFS as surrogates 
for OS in metastatic STS was conducted [8]. The study 
was however limited to the analysis of aggregated data.
We performed a meta-analysis of RCTs using IPD to 
assess the surrogate properties for OS of three commonly 
used endpoints in advanced STS: progression-free survival 
(PFS), time-to-progression (TTP) and time-to-treatment 
failure (TTF). This manuscript follows the international 
recommendations of the PRISMA guidelines for reporting 
meta-analyses [9]. 
RESULTS
Data
After screening 231 abstracts, we identified 21 
eligible trials and obtained the trial sponsor’s agreement 
for 19 RCTs (Figure 1). IPD were available for 14 RCTs 
[10–23]. Trials characteristics are presented in Table 1. 
Three trials had two experimental arms evaluating 
different administration schedules for the same drug 
[10, 15, 23]. We combined the two experimental arms 
into one for these studies. One trial was designed as two 
parallel randomized trials [14], it was included in the 
meta-analysis as two distinct trials so that we considered 
a total of 15 trials. Aside from one trial [18], RCTs 
evaluated chemotherapy-based regimens. Most trials 
compared an experimental chemotherapy to a doxorubicin 
or ifosfamide-based chemotherapy regimen as first-line 
treatment (Table 1). One trial focused on leiomyosarcomas 
[20] and one trial excluded liposarcomas [23], all 13 other 
trials presented similar histological subtypes. Out of the 14 
trials included, 11 relied on radiological central review at 
study entry and two trials used histology review (local or 
in a specialized center).
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IPD from the 2846 patients included in the trials 
were analyzed. Median follow-up duration ranged from 
9 to 93 months (median: 36 months). Figure 2 displays 
forest plots for the treatment effects estimated by hazard 
ratios (HR) on two-year OS, and one-year PFS, TTP and 
TTF for each trial. Among the 2165 patients who died 
during the total follow-up, 1704 (79%) died during the 
first 18 months. For each of the three candidate surrogate 
endpoints, the number of events observed at 6 and 12 
months is provided in Supplementary Table 1.
Correlation between the candidate surrogate 
endpoints and OS (individual-level surrogacy)
We relied on a one-parameter Clayton copula model, 
considered the best fitting model compared to Plackett or 
Hougaard copula. Considering a six-month follow-up for 
the surrogate endpoints, the individual-level correlations 
with 18-month OS were moderate, with PFS showing the 
highest correlation (0.62; 95% CI [0.59; 0.65]) (Table 2). 
Correlations obtained when using a one-year follow-up for 
Figure 1: Flow of information through the different phases of the study selection, as per PRISMA guidelines [9]*. 
*EORTC = European Organisation for Research and Treatment of Cancer; RCT = randomized controlled trial; STS = soft-tissue sarcoma.
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the surrogate endpoints were also moderate, even though 
slightly higher (PFS: 0.66; 95% CI [0.63; 0.68]).
Correlation between treatment effects on the 
candidate surrogate endpoints and treatment 
effect on OS (trial-level surrogacy)
A total of 15 pairs of log(HR) were compared for 
each endpoint. When considering a six-month follow-up 
for the surrogates, the trial-level associations R²WLR and 
R²2SM, were low (R²WLR ≤ 0.60; R²2SM ≤ 0.60) (Table 2). 
When considering a one-year follow-up, the association 
measures remained low (R²WLR ≤ 0.60; R²2SM ≤ 0.05). 
Regression curves calculated based on the WLR models 
are shown in Figure 3. As per IQWiG guidelines, all trial-
level associations estimated were ranked as medium.
Subgroup analyses
The first subgroup analysis focused on trials 
comparing systemic therapy to doxorubicin- or ifosfamide-
based chemotherapies in the first-line setting (Ntrial = 11; 
Npatient = 2243). When considering a six-month follow-
up, the three endpoints were moderately associated with 
18-month OS at the patient level (0.56 ≤ ρSpearman ≤ 0.67). 
At the trial level, the association between the candidate 
surrogates and 18-month OS was low (R²WLR ≤ 0.60; 
R²2SM ≤ 0.11) (Table 2). When considering a 12-month 
follow-up, the individual-level and trial-level associations 
increased. Confidence intervals for trial level associations 
were large, irrespective of the statistical method used. 
The number of events observed in the subgroup of 
trials at 6 and 12 months is provided in Supplementary 
Table 2. For the second subgroup analysis focusing on 
leiomyosarcomas, the treatment effects on OS and on 
the candidate surrogates could not be estimated for one 
trial due to a lack of events, it was then excluded from the 
subgroup analysis. Individual-level correlations slightly 
decreased compared to the primary analysis. At the trial 
level however, the correlations significantly increased 
(Table 2), although again, confidence interval were large.
DISCUSSION
We pooled IPD data from 2846 patients included 
in 14 RCTs to evaluate the surrogate properties of PFS, 
TTP and TTF for OS in advanced STS. At the individual-
level, associations between the three endpoints and OS 
were moderate, with the highest correlation observed for 
PFS. At the trial level, associations between the treatment 
effects on three endpoints and treatment effect on OS 
were low with wide confidence intervals. The strength 
of the trial-level association was quantified as medium as 
per the IQWiG criteria, indicating that the validity of the 
endpoints as surrogates for OS remains unclear.
Several statistical methods are available to assess 
surrogacy. We relied on the two-stage approach developed 
by Buyse and Burzykowski based on IPD [4], considered 
the most rigorous statistical approach for surrogacy 
assessment [5, 6]. Similarly, several criteria have been 
proposed to assess the validity of surrogate endpoints 
[24–26]. Although they present differences, they all 
require a lower limit of the 95% CI for the trial-level 
correlation coefficient at least higher than 0.6 to definitely 
validate a surrogate endpoint. As such, there was no 
sufficient evidence to conclude for surrogacy. 
To the best of our knowledge, this is the second 
meta-analysis conducted in advanced STS patients, and 
Table 1: Key characteristics of the included trials*
Study Ref Phase Inclusion period N Treatment line Control arm Experimental arm
Median follow-up
All patients Patients alive
62901 [10] II ≥1991 334 1st line Doxorubicin Epirubicin 50.2 months 13.3 months
62941 [11] II ≥1995 86 1st and 2nd line Doxorubicin Docetaxel 35.9 months 10.9 months
62903 [12] III 1992–1995 315 1st line Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + 
GM-GSF
91.4 months 40.1 months
62962 [13] II ≥1997 95 1st line Doxorubicin Doxorubicin pegylated liposomal 35.2 months 14.5 months
62912 [14] II 1992–1994 78 2nd-line Ifosfamide5 g/m²/1 day Ifosfamide3 g/m²/3 days 30.6 months 16.2 months
1994–1996 103 1st line Ifosfamide5 g/m²/1 day Ifosfamide3 g/m²/3 days 35.5 months 6.6 months
62971 [15] III 1998–2001 326 1st line Doxorubicin Ifosfamide 51.7 months 43.1 months
GEIS9 [16] II 2003–2007 132 1st line Doxorubicin Intensified Doxorubicin + 
Ifosfamide
22.5 months 15.4 months
Palsar 1 [17] III 1994–1997 145 1st line MAID Intensified MAID 93.0 months 89.7 months
62072 [18] III 2008–2010 369 2nd to 5th line Placebo Pazopanib 14.6 months 12.2 months
Palsar 2 [19] III 2000–2008 87 1st line MAID MAID + MICE 22.3 months 21.4 months
Taxogem † [20] II 2006–2008 70 2nd line Gemcitabine Gemcitabine + Docetaxel + 
Lenograstime
32.5 months 24.9 months
62012 [21] III 2003–2010 455 1st line Doxorubicin Intensified Doxorubicin + 
Ifosfamide
56.4 months 30.7 months
62061 [22] II 2006–2008 118 1st line Doxorubicin Brostallicin 21.3 months 19.3 months
62091 [23] IIb/III ≥2011 133 1st line Doxorubicin Trabectedin 9.4 months 8.6 months
*GM-GSF: Recombinant human granulocyte-macrophage colony-stimulating factor; MAID = Doxorubicin, Ifosfamide and Dacarbazine; MICE: Mesna, Ifosfamide, Carboplatin and Etoposide; Ref = 
reference.
†Only patients with leiomyosarcoma included.
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the first on IPD. In the first meta-analysis, conducted on 
aggregated data, the authors reported a 0.61 trial-level 
association when assessing the surrogate properties of PFS, 
and concluded that PFS was an appropriate surrogate for 
OS [8]. However, we feel that data were insufficient to 
provide strong surrogacy evidence. No confidence interval 
for the trial-level association was reported, a key element 
to quantify the validity of a surrogate endpoint using 
appropriate criteria [24–26]. As the correlation estimate 
reported was derived from a smaller set of trials than in 
our study, it is likely that the precision was also poor. 
Our study also presents some limitations. Some 
of the trials included date back to the 90 s. This should 
be regarded as a weakness, particularly with respect to 
the histological diagnosis. For instance, gastro-intestinal 
stromal tumors were considered as STS and included in 
some older trials. Additionally, the criteria for response 
assessment in solid tumors evolved in the past 20 years 
Figure 2: Forest plots. *Treatment effects on 12-month progression-free survival (A), time-to progression (B) and time-to-treatment 
failure (C) and on 18-month overall survival (OS) estimated by hazard ratios (HR) using separate Cox models. The first row for each trial 
shows the result for OS, and the second row shows the result for the candidate surrogate. The diamonds and squares represent the point 
estimates for OS and the candidate surrogate, respectively. The horizontal error bars show the 95% confidence interval (CI) of each hazard 
ratio (15 trials, 2846 patients). CT = control treatment; ET = experimental treatment.
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(WHO criteria, RECIST criteria). Finally, we could not 
include all relevant trials, as some of the sponsors and/
or PIs did not agree to share their data. This is a recurrent 
challenge when performing a meta-analysis [34]. Trial 
design for advanced sarcoma is particularly challenging 
due to the rarity and the heterogeneity of the disease and 
treatments, which may contribute to weaken the observed 
correlations between candidate surrogates and OS [27]. 
Most STS trials include different clinical phenotypes 
to increase their statistical power, even though specific 
RCTs would be required [27–29]. In the present study, 
the distribution of sarcoma subtypes across trials was 
highly variable, with proportions ranging from 0% [20] 
to 18% [16] for liposarcoma, 18% [19] to 100% [20] for 
leiomyosarcoma and 0% [20] to 14% [22] for synovial 
sarcoma. Locally advanced and metastatic patients have 
different prognoses, yet they are often conflated in trials 
as “advanced” sarcomas. Heterogeneity in terms of 
sarcoma subtypes might benefit the treatment in terms of 
OS, but, pre-supposing the drug is inactive, not in terms 
of PFS. Additionally, assuming the treatment is mainly 
efficient on specific histological subtypes, the treatment 
effects estimations might be diluted when all subtypes are 
combined. Heterogeneity in terms of treatment settings 
remains between the trials included in our study, which 
could also have weakened the association between the 
candidate surrogates and OS. Indeed, 11 trials included 
only first-line treatment (79% of all patients), one trial 
included first and second line treatments (3% of patients), 
one trial included 2nd line treatment only (3% of patients) 
and one trial included second to fifth line treatments 
(13% of patients). Central review at study entry is also 
Table 2: Individual- and trial-level associations between 6-month and 12-month progression-free survival, time-to-
progression, time-to-treatment failure and 18-month overall survival*
Individual-level association Trial-level association
Folow-up Endpoint ρSpearman† [95% CI] R²WLR‡ [95% CI] R²2SMφ [95% CI]
All trials (Ntrial = 15; Npatient = 2846)
6 months PFS 0.62 [0.59; 0.65] 0.33 [0.00; 0.60] 0.04 [0.00; 0.43]
TTP 0.59 [0.56; 0.63] 0.32 [0.00; 0.58] 0.07 [0.00; 0.60]
TTF 0.60 [0.57; 0.63] 0.32 [0.00; 0.58] 0.06 [0.00; 0.57]
12 months PFS 0.66 [0.63; 0.68] 0.33 [0.00; 0.60] 0.00 [0.00; 0.05]
TTP 0.63 [0.60; 0.66] 0.30 [0.00; 0.57] 0.00 [0.00; 0.02]
TTF 0.64 [0.61; 0.67] 0.31 [0.00; 0.58] 0.00 [0.00; 0.01]
Doxorubicin- or ifosfamide-based treatment, first-line setting (Ntrial = 11; Npatient = 2243)
6 months PFS 0.63 [0.60; 0.67] 0.30 [0.00; 0.60] 0.00 [0.00; 0.08]
TTP 0.60 [0.56; 0.64] 0.26 [0.00; 0.58] 0.00 [0.00; 0.11]
TTF 0.61 [0.57; 0.65] 0.27 [0.00; 0.58] 0.00 [0.00; 0.06]
12 months PFS 0.67 [0.64; 0.70] 0.39 [0.00; 0.66] 0.08 [0.00; 0.86]
TTP 0.64 [0.61; 0.68] 0.31 [0.00; 0.61] 0.12 [0.00; 1.00]
TTF 0.65 [0.62; 0.68] 0.32 [0.00; 0.62] 0.10 [0.00; 1.00]
Leiomyosarcomas (Ntrial = 14; Npatient = 1025)
6 months PFS 0.57 [0.51; 0.62] 0.59 [0.15; 0.76] 0.91 [0.00; 1.00]
TTP 0.55 [0.49; 0.60] 0.58 [0.13; 0.75] 0.97 [0.00; 1.00]
TTF 0.53 [0.48; 0.58] 0.59 [0.14; 0.76] 0.91 [0.00; 1.00]
12 months PFS 0.59 [0.54; 0.64] 0.59 [0.16; 0.75] 0.91 [0.00; 1.00]
TTP 0.52 [0.47; 0.58] 0.58 [0.15; 0.75] 0.97 [0.00; 1.00]
TTF 0.53 [0.48; 0.58] 0.58 [0.15; 0.75] 0.91 [0.00; 1.00]
*CI = confidence interval; PFS = progression-free survival; TTF = time-to-treatment failure; TTP = time-to-progression.
†ρSpearman represents the Spearman rank correlation coefficient between the candidate surrogates and overall survival.
‡R²WLR represents the coefficient of determination between treatment effect on the candidate surrogates and overall 
survival based on weighted linear regression models.
φR²2SM represents the coefficient of determination between treatment effect on the candidate surrogates and overall 
survival based on the two-stage model [4].
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likely to interfere. Patients with inappropriate histological 
subtypes or grades could be included and thus dilute the 
associations. A majority of the trials included in our study 
performed radiological central review, and some reviewed 
histology locally or in a specialized center. Results from 
our sensitivity analysis on doxorubicin- or ifosfamide-
based therapies as first-line metastatic treatment did 
not significantly differ from our main analysis. We 
estimated a higher trial-level association between the 
surrogate candidates and OS when focusing on patients 
with leiomyosarcomas. However, the individual-level 
associations were lower than in the primary analysis. This 
could be due to the limited number of patients included in 
the subgroup analysis. As a result, even though the results 
might seem promising, a larger IPD meta-analysis specific 
to leiomyosarcomas would be necessary to properly 
conclude. These factors should be accounted for when 
interpreting the statistically non-significant correlations 
observed in this meta-analysis. 
Finally, absence of surrogacy could also be 
explained if the candidate endpoints (PFS, TTP, TTF) do 
not truly predict OS. Indeed, Booth and Eisenhauer, for 
example, have questioned the mechanisms of actions of 
some agents, especially those targeting cell signaling and 
angiogenesis, and whether with chronic administration, 
they could delay progression for a time but lead to 
evolutionary changes in tumors, producing a more 
aggressive phenotype after treatment, thus offsetting the 
earlier delay in progression [30]. 
In addition, absence of surrogacy evidence might 
be related to an absence of the treatment effect on OS. 
The Accelerated Approval regulations, instituted by the 
Food and Drug Administration (FDA) in 1992, allow 
drugs for serious conditions that filled an unmet medical 
need to be approved based on a surrogate endpoint. 
Using a surrogate endpoint enabled the FDA to approve 
these drugs faster. As a result, an increasing number of 
anticancer drug product approvals by the FDA are made 
based on endpoints other than OS [1, 31, 32], some with 
no sufficient proof of their surrogate validity for OS [32]. 
In advanced STS for instance, FDA granted approval 
for pazopanib in 2012 based on proof of benefit for PFS 
[18], even though at the time no study had assessed trial-
level association between PFS and OS. In the context 
of accelerated approval, the FDA guidance on the term 
unmet medical need is imprecise. While this is not an 
issue in advanced sarcoma, recent data have shown that 
this term can often be overused [33], and as such the 
use of surrogates through pathways such as accelerated 
approvals, may be far greater than conditions with true 
unmet needs [34]. This issue is well illustrated with the 
example of bevacizumab in metastatic breast cancer; 
following accelerated approval based on PFS results, 
this drug was subsequently withdrawn following the 
publication of OS data [35, 36].
Several conditions have to be met to ensure adequate 
validation of a surrogate endpoint: (i) a significant 
quantity of high-quality data, both in terms of trials and 
patients, (ii) homogeneity, in terms of disease, settings, 
and mechanisms of action of the drugs, and (iii) strong 
statistical thresholds. Our meta-analysis did not lead to 
the validation of a surrogate in advanced sarcoma, as 
Figure 3: Trial-level association between treatment effects on the candidate surrogates and overall survival*. *Treatment 
effects estimated by the logarithm of hazard ratios (log[HR]) using the weighted linear regression approach. Each circle represents a trial, 
and the surface area of the circle is proportional to the size of the corresponding trial. PFS = progression-free survival; TTF = time-to-
treatment failure; TTP = time-to-progression; OS = overall survival.
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such OS should remain the primary endpoint in phase III 
trials evaluating systemic treatments in metastatic STS. 
Nevertheless, we highlighted moderate individual-level 
associations between the surrogate candidates and OS. 
These alternative endpoints thus remain useful in testing 
new treatments [37] in earlier drug development stages, 
such as phase II trials, or in futility assessment [38, 39]. 
MATERIALS AND METHODS
This study is registered on the clinical trial registry 
clinicaltrials.gov (identifier: NCT02873923).
Study selection
We identified trials by using a computerized search 
on MEDLINE with the following search algorithm: 
“sarcoma” [MeSH] AND “randomized controlled trial” 
[Text Word] AND trial [Text Word]. We limited our 
research to trials published before April the 7th, 2016. 
We also searched for trials on ClinicalTrials.gov and 
by contacting European sponsoring groups (EORTC, 
UNICANCER). Trials were eligible if they met the 
following criteria: (i) phase II or III randomized trials 
on humans, (ii) evaluating therapies for adults with 
advanced (i.e. locally advanced or metastatic) STS, 
(iii) at least one time-to-event endpoint other than OS 
as outcome, (iv) published or soon to be published 
in French or English, (v) signed agreement from the 
principal investigator and the sponsor, and (vi) available 
IPD. 
Patients, data and outcomes
We gathered IPD from all eligible trials. We assessed 
the surrogate properties of PFS, TTP and TTF evaluated 
at six and twelve months for 18-month OS. Outcomes 
were defined following the international DATECAN 
guidelines [40]. When none of the events included in 
the definition was observed, 6- and 12-month PFS, TTP 
and TTF were censored at the date of last follow-up or 6 
months, respectively 12 months, of follow-up whichever 
came first. 
Surrogacy measures
The individual-level surrogacy was assessed 
following a copula-based approach [4]. The individual-
level associations were estimated by the Spearman rank 
correlation coefficient (ρSpearman) calculated from the copula 
parameter.
The trial-level surrogacy - the association between 
the treatment effects - was evaluated with two frameworks. 
Using a weighted linear regression model (WLR), treatment 
effects on OS and PFS/TTP/TTF were estimated separately 
for each trial, based on the logarithm of the hazard ratios 
(log[HR]) using Cox proportional hazard models. We 
assessed the association between the treatment effects 
using the coefficient of determination (R²WLR) of a linear 
regression model weighted by the trial size. The second 
method follows the two-stage model (2SM) adapted to 
time-to-event endpoints introduced by Burzykowski et al. 
[4]. We first simultaneously estimated the treatment effects 
on OS and on the candidate surrogate endpoints in each 
trial using a bivariate survival model based on a one-
parameter Clayton copula. This approach enables taking 
into account the correlation between the endpoints in the 
estimation of the HR. We then estimated the association 
between the treatment effects (Weibull-distribution-based 
log[HR]) using an error-in-variable model, which allows 
taking into account the estimation errors. We assessed the 
trial-level association using the coefficient of determination 
(R²2SM).
All analyses were on an intention-to-treat basis. 
We reported confidence intervals for a 95% two-sided 
confidence-level (95% CI). All analyses were performed 
using SAS software v9.3 following Burzykowski et al. [4].
Strength of association
The strength of the trial-level association was ranked 
according to the Institute for Quality and Efficiency in 
Health Care (IQWiG) guidelines [24]: high association 
(lower limit of the 95% CI of R² ≥ 0.72), low association 
(higher limit of the 95% CI of R² ≤ 0.49) or medium 
association (neither low nor high), meaning that the 
validity of the surrogate remains unclear. 
Subgroup analyses
To control for trials’ heterogeneity, we performed 
two subgroup analyses. Firstly, we retained only trials 
focusing on first line treatment that included doxorubicin- 
or ifosfamide-based therapies in the control arm. In 
the second analysis, we included only patients with 
leiomyosarcomas.
CONCLUSIONS
Even though we highlighted moderate individual-
level associations between the surrogate candidates and 
OS, our meta-analysis did not lead to significant evidence 
to validate PFS, TTP or TTF as surrogate markers for 
OS when assessing systemic treatment in advanced STS. 
PFS, TTP and TTF can be used as primary endpoints in 
phase II trials or as futility endpoints in phase III trials. 
However, OS should remain the primary endpoint in phase 
III trials until sufficient proof of surrogacy is provided. To 
achieve that goal, improvement in the conduct of sarcoma 
trials, particularly regarding the selection of histological 
subtypes, is necessary. 
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